Alkahest

Alkahest, a Grifols subsidiary founded in 2014, is a biotechnology company pioneering a novel approach to drug discovery by analyzing the plasma proteome to identify proteins that promote health or drive disease. Its proprietary platform integrates AI and multiomics with access to Grifols' vast biorepository of over 100 million plasma samples, enabling the discovery of both therapeutic candidates and biomarkers. The company's pipeline includes clinical-stage programs targeting neurodegenerative diseases like Alzheimer's and Parkinson's, as well as age-related conditions such as wet AMD, positioning it at the intersection of plasma science and precision medicine.

Integrated AI and multiomics analysis platform leveraging one of the world's largest plasma sample repositories (over 100 million samples) to discover novel therapeutic proteins and biomarkers linked to aging and disease.

Alkahest competes in the crowded neurodegenerative disease space against large pharma and biotech companies, but its platform-based approach using plasma proteomics is highly differentiated. Its primary competitive advantage is the non-replicable scale and depth of its proprietary plasma sample database, which is integrated with real-world health data.